Masitinib in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of masitinib for the treatment
of mild to moderate Alzheimer's Disease. Masitinib will be administered as add-on therapy in
patients who have been treated for a minimum of 6 months with a stable dose of cholinesterase
inhibitor (donepezil, rivastigmine or galantamine) and/or memantine.